Fulcrum Therapeutics Inc. (FULC) Tops Q4 EPS by 8c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q4 EPS of ($0.64), $0.08 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $4.23 million versus the consensus estimate of $1.31 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Sharon AI secures six-year compute deal with NVIDIA for Australia deployment
• Independent Bank receives regulatory approval for HCB Financial acquisition